Objective To investigate the inhibitory effects and therapeutic efficacy of 3% hypertonic saline combined with dexmedetomidine on the levels of serum interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), neuron-specific enolase (NSE), and central nervous system-specific protein (S100B) in patients with severe craniocerebral injury, and to provide new insights and methods for the treatment of patients with severe craniocerebral injury. Methods The prospective study selected 58 patients with craniocerebral injury admitted to Department of Neurosurgery, Jieyang People's Hospital from September 2022 to August 2023 as the study objects. The patients were randomly divided into a control group and an observation group by the single blind method. The control group took mannitol and other sedative and analgesic drugs; in addition, the observation group took 3% hypertonic saline and dexmedetomidine. The serum levels of IL-6, TNF-α, NSE, and S100B were measured 12 (T1), 24 (T2), 48 (T3), and 72 h (T4) after injury. The data were compared between the two groups by t and χ2 tests. Results The serum levels of IL-6, TNF-α, NSE, and S100B at T2, T3, and T4 in the observation group were (276.11±18.64) ng/L, (165.07±15.32) ng/L, and (126.07±16.15) ng/L, (1.27±0.21) ng/L, (1.22±0.25) ng/L, and (0.78±0.15) ng/L, (16.74±3.51) μg/L, (19.07±4.91) μg/L, and (14.97±2.21) μg/L, and (0.47±0.15) μg/L, (0.56±0.23) μg/L, and (0.32±0.16) μg/L, and those in the control group were (315.23±19.54) ng/L, (199.05±16.16) ng/L, and (141.02±17.98) ng/L, (1.47±0.25) ng/L, (1.45±0.22) ng/L, and (0.91±0.19) ng/L, (20.17±3.21) μg/L, (24.17±5.61) μg/L, and (17.06±2.98) μg/L, and (0.67±0.28) μg/L, (0.87±0.32) μg/L, and (0.47±0.13) μg/L, the difference between the two groups was statistically significant (all P<0.05). Conclusion Three percent hypertonic saline combined with dexmedetomidine can inhibit the expression of neuroinflammatory factors in patients with severe craniocerebral injury and alleviate secondary brain injury.